chapter 7 references -...
TRANSCRIPT
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 183
Abdelwahed W, Degobert G, Stainmesse S, Fessi H (2006). Freeze drying of
nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev.
58: 1688–713.
AHFS Drug Information (2002). American Society of Health-System Pharmacists,
edited by G.K. McEvoy, pp. 1313-1317.
Ahlin P, Kristl J, Kristl A, Vrecer F (2002). Investigation of polymeric nanoparticles
as carriers of enalaprilat for oral administration. Int J Pharm. 239: 113-20.
Ahmad S, Jain GK, Faiyazuddin M, Iqbal Z, Talegaonkar S, Sultana Y, Ahmad FJ
(2009). Stability-indicating high-performance thin-layer chromatographic method for
analysis of terbinafine in pharmaceutical formulations. Acta Chromatogr. 4: 631–
639.
Ahuja S, Ashman J (1990). Terbutaline sulfate. In Analytical Profiles of Drug
Substances edited by K. Florey, Academic Press, New York, pp. 601-625, 1990.
Ali HSM, York P, Blagden N (2009). Preparation of hydrocortisone nanosuspension
through a bottom-up nanoprecipitation technique using microfluidic reactors. Int. J.
Pharm. 375: 107–113.
Ali R, Jain GK, Iqbal Z, Talegaonkar S, Pandit P, Sule S, Malhotra G, Khar RK,
Bhatnagar A, Ahmad F.J (2009a). Development and clinical trial of nano-atropine
sulfate dry powder inhaler as a novel organophosphorous poisoning antidote
Nanomedicine: Nanotechnology, Biology and Med. 5 (1): 55-63.
Altiere RJ, Thompson DC (1996). Pulmonary physiology and pharmacology of the
airways. In Inhalation Aerosols: Physical and Biological Basis for Therapy, pp.
96–9.
Anderson JM, Shive MS (1997). Biodegradation and biocompatibility of PLA and
PLGA microspheres. Adv Drug Del Rev. 28: 5-24.
Andersson KE, Nyberg L (1984). Pharmacokinetics of terbutaline therapy. Eur J
Respir Dis. 65 (134): 165- 170.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 184
Arnold K, Grass P, Knecht A, Roos R, Sluke G, Thieme H, Wenzel J (1995).
Inhalation powders and method of manufacturing them. Eur Patent 0663815.
Asthma and Allergies" (2008). National Institute for Occupational Safety and Health.
http://www.cdc.gov/niosh/topics/asthma/. Retrieved March 23, 2009.
Bailey MM, Berkland CJ (2009). Nanoparticle formulations in pulmonary drug
delivery. Med Res Rev. 29 196–212.
Bansil R, Turner BS (2006). Mucin structure, aggregation, physiological functions
and biomedical applications. Curr Opin Colloid Interface Sci. 11: 164–70.
Barron MK, Young TJ, Johnston KP, Williams III RO (2003). Investigation of
processing parameters of spray freezing into liquid to prepare polyethylene glycol
polymeric particles for drug delivery. AAPS PharmSciTech. 4: E12.
Bates DV, Fish BR, Hatch TF, Mercer TT, Morrow PE (1966). Deposition and
retention models for internal dosimetry of the human respiratory tract. Task group on
lung dynamics. Health Phys.12 (2): 173–207.
Bernard VE, Sofie V, Johan AM, Jan V, Ludo F, Jan VH, Guy VM, Patrick A (2008).
Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during
freeze-drying of drug nanosuspensions–A case study with itraconazole. Eur J Pharm
Biopharm. 70(2): 590-596.
Bernhard W, Haslam PL, Floros J (2004). From birds to humans: new concepts on
airways relative to alveolar surfactant. Am J Respir Cell Mol Biol. 30: 6–11.
Bhavna, Ahmad F, Khar R, Sultana S, Bhatnagar A (2009). Techniques to develop
and characterize nanosized formulation for salbutamol sulfate. J Mater Sci Mater
Med. 20: 71–76.
Bilati U, All´emann E, Doelker E (2005). Development of a nanoprecipitation method
intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm
Sci. 24: 67–75.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 185
Biradar SV, Patil AR, Sudarsan GV, Pokharkar VB (2006). A comparative study of
approaches used to improve solubility of roxithromycin. Powder Technol. 169 (1),
24: 22-32.
Bisgaard H (1996). Drug delivery frominhaler devices. Lung deposition, clinical
effect and cost effectiveness vary. Br Med J. 313: 895–896.
Blondino LFE, Hindle M, Soine WH, Byron PR (2005). Stability and characterization
of perphenazine aerosols generated using the capillary aerosol generator. Int J
Pharm. 303: 113–124.
Borgstrom L, Newman S, Wheisz A, MorCn F (1992). Pulmonary distribution of
inhaled terbutaline: comparison of scanning gamma camera and urinary excretion
methods. J Pharm Sci. 81: 753-755.
Borgstrom L, Nilsson M (1990). A method for determination of the absolute
pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res. 7: 1069-1070.
Borm P, Klaessig FC, Landry TD, Moudgil B, Pauluhn J, Thomas K, Trottier R,
Wood S (2006). Research strategies for safety evaluation of nanomaterials, Part V:
Role of dissolution in biological fate and effects of nanoscale particles. Toxicol Sci.
90: 23–32.
Bosch HW, Ostrander KD, Cooper ER (2002). Dry powder aerosols of
nanoparticulate drugs. US20020102294.
Bouzigon E, Corda E, Aschard H. (2008). Effect of 17q21 Variants and Smoking
Exposure in Early-Onset Asthma. New Eng Jour Med. 359 (19): 1985–89.
Braun MA, Oschmann R, Schmidt PC (1996). Influence of excipients and storage
humidity on the deposition of disodium cromoglycate (DSCG) in the Twin Impinger.
Int J Pharm. 135: 53–62.
Brittain HG, Fiese EF (1999). Effects of pharmaceutical processing on drug
polymorphs and solvates, In Polymorphism in Pharmaceutical Solids edited by
H.G. Brittain, Marcel Dekker Inc, New York, USA.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 186
Buhling F, Waldburg N, Reisenauer A, Heimburg A, Golpon H, Welte T (2004).
Lysosomal cysteine proteases in the lung: role in protein processing and
immunoregulation. Eur Respir J. 23: 620–28.
Bulsara PA, Roche TC (2005). Dry Powder Composition. US20050244340.
Burgess DJ (2005). Injectable dispersed systems — formulation, processing, and
performance, Taylor & Francis Group, USA.
Byron PR (2004). Drug delivery devices: issues in drug development. Proc Am
Thoracic Soc. 1: 321–328.
Calleja I, Blanco-Prˇııeto MJ, Ruz N, Renedo MJ, Dios-Vi ´ eitez MC (2004). High-
performance liquid-chromatographic determination of rifampicin in plasma and
tissues. J Chromatogr A. 1031: 289–294.
Chan HK (2006). Dry powder aerosol delivery systems: current and future research
directions. J Aerosol Med. 19: 21–35.
Chan HK (2006a). Dry powder aerosol delivery systems: current and future research
directions. J Aerosol Med. 19 (1): 21-27.
Chan HK, Chew NYK (2003). Novel alternative methods for the delivery of drugs for
the treatment of asthma. Adv Drug Deliv Rev. 55: 793–805.
Chan HK, Eberl S, Glover W (2006). Radiolabelling of pharmaceutical aerosols and
gamma scintigraphic imaging for lung deposition. In Encyclopaedia of
Pharmaceutical Technology edited by J. Swarbrick, Informa Healthcare, New York,
pp. 3094–3107.
Chawla A, Taylor KMG, Newton JM, Johnson MCR (1994). Production of spray-
dried salbutamol sulphate for use in dry powder aerosol formulation. Int J Pharm.
108: 233-240.
Chen JF, Zhou MY, Shao L, Wang YY, Yun J, Chew NY, Chan HK (2004).
Feasibility of preparing nanodrugs by high-gravity reactive precipitation, Int. J.
Pharm. 269: 267–274.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 187
Chen X, Young TJ, Sarkari M, Williams III RO, Johnston KP (2002). Preparation of
cyclosporine a nanoparticles by evaporative precipitation into aqueous solution. Int J
Pharm. 242: 3–14.
Chiang PC, Alsup J, Lai Y, Hu Y, Heyde B, Tung D (2009). Evaluation of aerosol
delivery of nanosuspension for pre-clinical pulmonary drug delivery. Nanoscale Res
Lett. 4: 254–261.
Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N (2010). Rapid translocation
of nanoparticles from the lung airspaces to the body. Nat Biotechnol. 28: 1300–3.
Chougule MB, Padhi BK, Jinturkar KA, Misra A (2007). Development of Dry
Powder Inhalers. Recent Patents Drug Del Formulation. 1: 11-21.
Chow AHL, Tong HHY, Chattopadhyay P, Shekunov BY (2007). Particle
engineering for pulmonary drug delivery. Pharm Res. 24: 411–437.
Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, Lyapustina S,
Mitchell J, Rogers B, Strickland H, Tougas T, Tsong Y, Wyka B
(2003). Considerations for the development and practice of cascade impaction testing
including a mass balance failure investigation tree. J Aerosol Med. 16: 235-247.
Chrystyn H (2006). Closer to an ‘Ideal Inhaler’ with the Easyhaler: an innovative dry
powder inhaler. Clin Drug Invest. 26: 175–183.
Cipolla D, Johansson, E. (2008). AERx pulmonary drug delivery systems. In
Modified Release Drug Delivery Technology (2nd Edn) edited by M.J. Rathbone, J.
Hadgraft, M.S. Roberts, M.E. Lane, pp. 563–571.
Clark AR (1995). Medical aerosol inhalers: past, present and future. Aerosol Sci
Technol. 22: 374–391.
Clunes MT, Boucher RC (2007). Cystic fibrosis: the mechanisms of pathogenesis of
an inherited lung disorder. Drug Discov Today Dis Mech. 4: 63–72.
Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER (1982). Cell number and cell
characteristics of the normal human lung. Am Rev Respir Dis. 126: 332–7.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 188
Crowder TM (2003). A guide to pharmaceutical particulate science. Boca Raton,
Florida: Interpharm Press/CRC.
Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB (2002).
Fundamental effects of particle morphology on lung delivery: predictions of Stokes’
law and the particular relevance to dry powder inhaler formulation and development.
Pharm Res. 19: 239–245.
Cryan SA, Sivadas N, Garcia-Contreras L (2007). In vivo animal models for drug
delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 59: 1133– 151.
D. Heng, D.J. Cutler, H.K. Chan, J. Yun, J.A. Raper (2008). What is a suitable
dissolution method for drug nanoparticles? Pharm Res. 25: 1696–1701.
Dai WG, Dong LC, Song WQ (2007). Nanosizing of a drug/carrageenan complex to
increase solubility and dissolution rate. Int J Pharm. 342 (1-2): 201-207.
Dailey la, Schmehl T, Gessler T, Wittmar M, Grimminger F, Seeger W, Kissel T
(2003). Nebulization of biodegradable nanoparticles, impact of nebulizer technology
and nanoparticles characteristics on aerosol features. J Control Rel. 86: 131-44.
Dalvi SV, Dave RN (2009). Controlling particle size of a poorly water-soluble drug
using ultrasound and stabilizers in antisolvent precipitation. Ind Eng Chem Res. 48:
7581–7593.
Dalvi SV, Khopadhyay M (2009). A novel process for precipitation of ultra-fine
particles using sub-critical CO2. Powder Tech. 195(3): 190-195.
Daraghmeh N, Al-Omari MM, Sara Z, Badwan AA, Jaber AMY (2002).
Determination of terbutaline sulfate and its degradation products in pharmaceutical
formulations using LC. J Pharm Biomed Anal. 29: 927–937.
Darquenne C, Prisk G.K (2008). Deposition of inhaled particles in the human lung is
more peripheral in lunar than in normal gravity. Eur J Appl Physiol. 103: 687–695.
Davies NM, Feddah MR (2003). A novel method for assessing dissolution of aerosol
inhaler products. Int J Pharm. 255: 175–187.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 189
Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H,
Weers JG (2000). Hollow porous particles in metered dose inhalers. Pharm Res. 17:
168-174.
Deng Z, Xu S, Li S (2008). Understanding a relaxation behavior in a nanoparticle
suspension for drug delivery applications. Int J Pharm. 351: 236–243.
Dhumal RS, Biradar SV, Paradkar AR, York P (2009). Particle engineering using
sonocrystallization: salbutamol sulphate for pulmonary delivery. Int J Pharm. 368
129–137.
Dickinson PA, Howells SW, Kellaway IW (2001). Novel nanoparticles for pulmonary
drug administration. J Drug Target. 9: 295–302.
Dickson LC, Mac Neil JD, Lee S, Fesser AC (2005). Determination of beta-Agonist
Residues in Bovine Urine Using Liquid Chromatography-Tandem Mass
Spectrometry. JAOAC Int. 88: 46–56.
Dixon DJ, Johnston KP, Bodmeier RA (1993). Polymeric material formed by
precipitation with a compressed fluid antisolvent. AIChE J. 39: 127-139.
Dolenc A, Kristl J, Baumgartner S, Planinšek O (2009). Advantages of celecoxib
nanosuspension formulation and transformation into tablets. Int J Pharm. 376(1-2):
204-212.
Dolovich MB (2009). 18F-fluorodeoxyglucose positron emission tomographic
imaging of pulmonary functions, pathology, and drug delivery. Proc Am Thorac
Soc. 6: 477–485.
Dong Y, Ng WK, Shen S, Kim S, Tan Reginald BH (2009). Preparation and
characterization of spironolactone nanoparticles by antisolvent precipitation. Int J
Pharm. 375 (1-2): 84-88.
Dong Y, Wai Kiong Ng, Jun Hu, Shoucang S, Reginald BH Tan (2010). A continuous
and highly effective static mixing process for antisolvent precipitation of
nanoparticles of poorly water-soluble drugs. Int J Pharm. 386 (1-2): 256-261.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 190
Duddu SP, Sisk SA, Walter YH, Tarara TE, Trimble KR, Clark AR, Eldon MA, Elton
RC, Pickford M, Hirst PH, Newman SP, Weers JG (2002). Improved lung delivery
from a passive dry powder inhaler using an engineered Pulmosphere®powder. Pharm
Res. 19: 689-695.
Dunbar C (2002). Dry powder formulations for inhalation. Drug Deliv Syst Sci. 2:
78–80.
Eberl S, Chan HK, Daviskas E (2006). Spect imaging for radioaerosol deposition and
clearance studies. J Aerosol Med. 19: 8–20.
Edwards D, Batvcky R, Johnston L (2004). Highly efficient delivery of a large
therapeutic mass aerosol. US20040076589.
Edwards D, Caponetti G, Hrkach JS, Lotan N, Hanes J, Langer RS, Ben-jebria AA
(2001). Porous Particles for deep lung delivery. US 20010033830.
Edwards DA, Caponetti GH, Jeffrey S, Lotan N, Justin Ben-Jebria AA, Langer RS
(2005). Development of dry powder inhaler. US20050244341.
Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML (1997).
Large porous particles for pulmonary drug delivery. Science. 276 (5320): 1868–1871.
Edwards DA, Sung J, Pulliam B, Wehrenberg-Klee E, Schwartz E, Dreyfuss P,
Kulkarni S, Lieberman E (2005a). Pulmonary delivery of malarial vaccine in the form
of particulates. WO2005110379.
Eerdenbrugh BV, den Mooter GV, Augustijns P (2008). Top-down production of drug
nanocrystals: nanosuspension stabilization, miniaturization and transformation into
solid products. Int J Pharm. 364 64–75.
El-Chemaly S, Pacheco-Rodriguez G, Ikeda Y, Malide D, Moss J (2009). Lymphatics
in idiopathic pulmonary fibrosis: new insights into an old disease. Lymphat Res Biol.
7: 197–203.
Embleton JK (2000). Inhalation Powders. WO0033789.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 191
Engstrom J, Lai E, Ludher B, Chen B, Milner T, Williams R, Kitto G, Johnston K
(2008). Formation of stable submicron protein particles by thin film freezing. Pharm.
Res. 25: 1334–1346.
Engstrom J, Tam J, Miller M, Williams III RO, Johnston K (2009). Templated open
flocs of nanorods for enhanced pulmonary delivery with pressurized metered dose
inhalers. Pharm Res. 26: 101–117.
Fagerstrom PO (1984). Pharmacokinetics of terbutaline after parenteral
administration. Eur J Respir Dis Suppl. 134: 101-110.
Fanta CH (2009). Asthma. N Engl J Med. 360 (10): 1002–14.
Fesser AC, Dickson LC, MacNeil JD, Patterson JR, Lee S, Gedir R (2005).
Determination of beta-agonists in liver and retina by liquid chromatography-tandem
mass spectrometry. J AOAC Int. 88 (1): 61-69.
Flament MP, Leterme P, Gayot A (2004). The influence of carrier roughness on
adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from
dry powder inhalers. Int J Pharm. 275 (1-2): 201-209.
Foster TP, Leatherman MW (1995). Powder characteristics of proteins spray-dried
from different spray-dryers. Drug Dev Ind Pharm. 21: 1705–1723.
Furuyama A, Kanno S, Kobayashi T, Hirano S (2009). Extrapulmonary translocation
of intratracheally instilled fine and ultrafine particles via direct and alveolar
macrophage-associated routes. Arch Toxicol. 83: 429–37.
Galindo-Rodriguez S, All´emann SE, Fessi H, Doelker E (2004). Physicochemical
parameters associated with nanoparticle formation in the saltingout, emulsification–
diffusion, and nanoprecipitation methods. Pharm Res. 21: 1428–1439.
Gallagher PM, Cof fey MP, Krukonis VJ, Klasutis N (1989). Gas antisolvent
recrystllization: New process to recrystallize compounds insoluble in supercritical
fluids. In Supercritical Fluid Science and Technology edited by K.P. Johnston and
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 192
Gao L, Zhang D, Chen M, Duan C, Dai W, Jia L, Zhao W (2008). Studies on
pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int J Pharm.
355 (1-2): 321-327.
Garekani HA, Sadeghi F, Badiee A, Mostafa SA, Rajabi-Siahboomi AR (2001).
Crystal habit modifications of ibuprofen and their physicomechanical characteristics.
Drug Dev Ind Pharm. 27 (8): 803–809.
Gazic I, Bosak A, Sinko G, Vinkovic V, Kovarik Z. Preparative HPLC separation of
bambuterol enantiomers and stereoselective inhibition of human cholinesterases
(2006). Anal Bioanal Chem. 385: 1513–1519.
Geiser M (2010). Update on macrophage clearance of inhaled micro- and
nanoparticles. J Aerosol Med Pulm Drug Deliv. 23: 207–17.
Gonda I (2004). Targeting by deposition. In Pharmaceutical Inhalation Aerosol
Technology edited by A.J. Hickey, Marcel Dekker, Inc., New York, USA, pp. 65–88.
Gupta R, Hindle M, Byron PR, Cox KA, McRae DD (2003). Investigation of a novel
condensation aerosol generator: solute and solvent effects. Aerosol Sci Technol. 37:
672–681X.
Hartwig S, Heike GB (2004). A novel spray-drying technique to produce low density
particles for pulmonary delivery. Int J Pharm. 278 (1): 187-195.
Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H (2010).
Choosing inhaler devices for people with asthma: current knowledge and outstanding
research needs. Respir Med. 104: 1237–1245.
Herring VL, Johnson JA (2000). Simple method for determination of terbutaline
plasma concentration by high-performance liquid chromatography. J Chromatogr B
Biomed Sci Appl. 741 (2): 307-12.
Hersch EM, Petersen EA, Proffitt RT, Bracken KR, Chiang SM (1999). Antibiotic
formulation and use for bacterial infections. US5958449.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 193
Hersey JA (1975). Ordered mixing: a new concept in powder mixing practice.
Powder Technol. 11: 41–44.
Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W (1986). Deposition of
particles in the human respiratory tract in the size range 0.005–15 [mu]m. J Aerosol
Sci. 17: 811–25.
Hezave AZ, Esmaeilzadeh F (2010). Micronization of drug particles via RESS proces.
J Supercrit Fluids. 52 (1): 84-98.
Hickey AJ, Concessio NM (1997). Descriptors of irregular particle morphology and
powder properties. Adv Drug Deliv Rev. 26: 29–39.
Hickey AJ, Crowder, T.M (2007). Next generation dry powder inhalation delivery
systems. Lung Biol Health Dis. 221: 445–460.
Hickey AJ, Gonda I, Irwin WJ, Fildes FJ (1990). Effect of hydrophobic coating on the
behavior of a hygroscopic aerosol powder in an environment of controlled
temperature and relative humidity. J Pharm Sci. 79 (11): 1009–1014.
Hickey AJ, Martonen TB (1993). Behavior of hygroscopic pharmaceutical aerosols
and the influence of hydrophobic additives. Pharm Res. 10 (1): 1–7.
Hinds WC (1999). Uniform Particle Motion. Aerosol Technology: Properties,
Behavior and Measurement of Airborne Particles (2nd Edn.), pp. 53–5.
Hinrichs WLJ, Mancenido FA, Sanders NN, Braeckmans K, De Smedt SC,
Demeester J (2006). The choice of a suitable oligosaccharide to prevent aggregation
of PEGylated nanoparticles during freeze-thawing and freeze drying. Int J Pharm.
311: 237–44.
Hirst PH, Pitcairn GR, Weers JG, Tarara TE, Clark AR, Dellamary LA, Hall G, Shorr
J, Newman SP (2002). In vivo deposition of hollow porous particles from a
pressurized metered dose inhaler. Pharm Res. 19: 258-264.
Hochhaus G, Möllmann H (1992). Pharmacokinetic/pharmacodynamics
characteristics of the β2-agonists terbutaline, salbutamol and Fenoterol. Int J Clin
Pharmacol. 30 (9): 342-362.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 194
Hodson PD, Smith DK, Velasquez DJ, Wass ACL, Calhoun CD (1998). Dry powder
inhalation device with elongate carrier for power. US5740793.
Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL (2008). Regulation of
immunological homeostasis in the respiratory tract. Nat Rev Immunol. 8: 142–52.
Hong JN, Hindle M, Byron PR (2002). Control of particle size by coagulation of
novel condensation aerosols in reservoir chambers. J Aerosol Med. 15: 359–368.
Hsu CH, Robinson CP, Basmadjian GP (1994). Tissue distribution of 3H-terbutaline
in rabbits. Life Sciences. 54 (20): 1465-1469.
http://www.ginasthma.org/pdf/GINA_Report_2010.pdf
Hu T, Chiou H, Chan HK, Chen JF, Yun J (2008). Preparation of inhalable
salbutamol sulphate using reactive high gravity controlled precipitation. J Pharm Sci.
97: 944–949.
Hussein K, Türk M, Wahl MA (2008). Drug loading into β-cyclodextrin granules
using a supercritical fluid process for improved drug dissolution. Eur J Pharm Sci. 3
(3): 306-312.
J.M.L. Penninger, ACS Symposium Series 406, American Chemical Society:
Washington DC, pp. 334-354.
Jaafar-Maalej C, Andrieu V, Elaissari A, Fessi H (2009). Assessment methods of
inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv. 6:
941–959.
Jacob JS, Jong YS, Abramson DT, Mathiowitz E, Santos CA (2005). Nanoparticulate
therapeutic biologically active agents. US2005181059.
Jacobs C, Muller RH (2002). Production and characterization of a budesonide
nanosuspension for pulmonary administration. Pharm Res. 19: 189-94.
James J, Crean B, Davies M, Toon R, Jinks P, Roberts CJ (2008). The surface
characterisation and comparison of two potential submicron, sugar bulking excipients
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 195
for use in low-dose, suspension formulations in metered dose inhalers. Int J Pharm.
361: 209–221.
Jenne JW, Tashkin DP (1993). Beta-adrenergic agonists. In Bronchial Asthma,
Mechanisms and Therapeutics (3rd Edn) edited by E.B. Weiss & M. Stein, Little,
Brown and Company, pp. 700–748.
Joshi MR, Misra AN (1999). Liposomes of terbutaline sulfate: in vitro and in vivo
studies. Indian J Exp Biol. 37 (9): 881-887.
Keck CM, Müller RH (2006). Drug nanocrystals of poorly soluble drugs produced by
high pressure homogenization. Eur J Pharm Biopharm. 62: 3–16.
Kesisoglou F, Panmai S, Wu Y (2007). Nanosizing — oral formulation development
and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59: 631–644.
Kim KH, Kim HJ, Kim JH, Shin SD (2001). Determination of terbutaline enantiomers
in human urine by coupled achiral-chiral high-performance liquid chromatography
with fluorescence detection. J Chromatogr B Biomed Sci Appl. 10, 751 (1): 69-77.
Kim YH, Sioutas C, Fine P, Katherine S. Shing KS (2008). Effect of albumin on
physical characteristics of drug particles produced by supercritical fluid technology.
Powder Technol. 182 (3): 354-363.
Korn SH, Wouters EF, Wesseling G, Arends JW, Thunnissen FB (1998). Interaction
between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor
mRNA expression in human bronchial epithelial cells. Biochem Pharmacol. 15, 56
(12): 1561-1569.
Kumar TMP, Shivakumar HG (2006). Novelcore in cup buccoadhesive systems and
films of terbutaline sulphate. Asian J Pharm Sci. 1 (3-4): 175-187.
Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang YY, Cone R (2007). Rapid
transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl
Acad Sci. 104: 1482–7.
Lai SK, Wang YY, Hanes J (2009). Mucus-penetrating nanoparticles for drug and
gene delivery to mucosal tissues. Adv Drug Deliv Rev. 61: 158–71.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 196
Lee J, Lee SJ, Choi JY, Yoo JY, Ahn CH (2005). Amphiphilic amino acid
copolymers as stabilizers for the preparation of nanocrystal dispersion. Eur J Pharm.
Sci. 24 (5): 441-449.
Lemanske RF, Busse WW (2010). Asthma: clinical expression and molecular
mechanisms. J Allergy Clin Immunol. 125 (2): S95–102.
Lengsfeld CS, Delplanque JP, Barocas VH, Randolph TW (2000). Mechanism
governing microparticle morphology during precipitation by a compressed
antisolvent: atomization vs nucleation and growth. J Phys Chem B. 104: 2725-2735.
Li S, Wang J, Zhao S. Determination of terbutaline sulfate by capillary
electrophoresis with chemiluminescence detection (2009). J Chromatogr B Analyt
Technol Biomed Life Sci. 15, 877 (3): 155-58.
Lippmann M, Schlesinger R (1984). Interspecies comparisons of particle deposition
and mucociliary clearance in tracheobronchial airways. J Toxico1 Environ Health.
13(2-3): 441-69.
Lipworth B (1996). Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 42:
697-705.
Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q (2009). In
vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm. 379(1):
181-186.
Lukas P, Anderson K, Staniforth JN (1998). Fine particles multiplets as perforemence
modifiers. Pharm Res. 15: 562-569.
Luo W, Zhu L, Deng J, Liu A, Guo B, Tan W, Dai R (2010). Simultaneous analysis of
bambuterol and its active metabolite Terbutaline enantiomers in rat plasma by chiral
liquid chromatography–tandem mass spectrometry. J Pharm Biomed Anal. 52, 227–
231.
Madl AK, Pinkerton KE (2009). Health effects of inhaled engineered and incidental
nanoparticles. Crit Rev Toxicol. 39: 629–658.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 197
Martín A, Cocero MJ (2008). Micronization processes with supercritical fluids:
fundamentals and mechanisms. Adv Drug Deliv Rev. 60: 339–350.
Martindale (1996). The Extra Pharmacopeia, 28th ed, The Royal Pharmaceutical
Society, London, pp. 1592-1593.
Martinez FD (2007). Genes, environments, development and asthma: a reappraisal.
Eur Respir J. 29 (1): 179–84.
Martonen TB, Katz I, Fults K, Hickey AJ (1992). Use of analytically defined
estimates of aerosol respirable fraction to predict lung deposition patterns. Pharm
Res. 9 (12): 1634–1639.
Maschke A, Calí N, Appel B, Kiermaier J, Blunk T Göpferich A (2006)
Micronization of Insulin by High Pressure Homogenization. Pharm Res. 23(9): 2220-
2229.
Mason, Robert J; Broaddus, V Courtney; Murray, John F; Nadel, Jay A (2005).
Asthma. Murray and Nadel's Textbook of Respiratory Medicine (4th Eds.), Elsevier.
Matsukawa Y, Lee VH, Crandall ED, Kim KJ (1997). Size-dependent dextran
transport across rat alveolar epithelial cell monolayers. J Pharm Sci. 86: 305–9.
Matteucci ME, Hotze MA, Johnston KP, Williams III RO (2006). Drug nanoparticles
by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir.
22: 8951–8959.
Mauludin R, Müller RH, Keck CM (2009). Development of an oral rutin nanocrystal
formulation. Int J Pharm. 370 (1-2): 202-209.
McWilliam AS, Holt PG, Gehr P (2000). Dendritic cells as sentinels of immune
surveillance in the airways. In Particle–Lung Interactions edited by P. Gehr & J.
Heyder, Marcel Dekker Inc., New York, pp. 473–489.
Mercer RR, Russell ML, Roggli VL, Crapo JD (1994). Cell number and distribution
in human and rat airways. Am J Respir Cell Mol Biol. 10: 613–24.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 198
Merkus HG (2008). Particle Size Measurements: Fundamentals, Practice, Quality,
Springer, USA.
Meziani MJ, Pathak P, Beacham F, Allard LF, Sun YP (2005). Nanoparticle
formation in rapid expansion of water-in-supercritical carbon dioxide microemulsion
into liquid solution. J Supercrit Fluids. 34(1): 91-97.
Mie A, Ray A, Axelsson BO, Jörntén-Karlsson M, Reimann CT (2008). Terbutaline
enantiomer separation and quantification by complexation and field asymmetric ion
mobility spectrometry-tandem mass spectrometry. Anal Chem. 80 (11): 4133-40.
Mitchell JP, Nagel MW (2003). Cascade impactors for the size characterization of
aerosols from medical inhalers: their use and limitations. J Aerosol Med.16: 341-377.
Moller W, Felten K, Sommerer K, Scheuch G, Meyer G, Meyer P (2008). Deposition,
retention, and translocation of ultrafine particles from the central airways and lung
periphery. Am J Respir Crit Care Med. 177: 426–32.
Moore WC, Pascual RM (2010). Update in asthma 2009. Am J Res Crit Care Med.
181 (11): 1181–7.
Moribe K, Fukino M, Tozuka Y, Higashi K, Yamamoto K (2009). Prednisolone
multicomponent nanoparticle preparation by aerosol solvent extraction system. Int J
Pharm. 380(1-2): 201-205.
Moulton B, Zaworotko MJ (2001). From molecules to crystal engineering:
supramolecular isomerism and polymorphism in network solids. Chem Rev. 101 (6):
1629–1658.
Muller RH, Jacobs C, Kayser O (2001). Nanosuspensions as particulate drug
formulations in therapy rationale for development and what we can expect for the
future. Adv Drug Deliv Rev. 47: 3–19.
Newman S, Hollingworth A, Clark A (1994). Effect of different modes of inhalation
on drug delivery from a dry powder inhaler. Int J Pharm. 102 (1):127–132.
Newman SP (2004). Dry powder inhalers for optimal drug delivery. Expert Opin
Biol Ther. 4: 23–33.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 199
Newman SP, Busse WW (2002). Evolution of dry powder inhaler design, formulation
and performance. Respir Med. 96: 293–304.
Newman SP, Busse WW (2002). Evolution of dry powder inhaler design,
formulation, and performance. Respir Med. 96: 293–304.
Newman SP, Clarke SW (1983). Therapeutic aerosols I—physical and practical
considerations. Thorax. 38: 881–886.
Newman SP, Clarke SW (1993). Bronchodilator delivery from Gentlehaler, a new
low-velocity pressurized aerosol inhaler. Chest. 103 (5):1442–1446.
Newman SP, Pitcairn GR, Hirst PH, Rankin L (2003). Radionuclide imaging
technologies and their use in evaluating asthma drug deposition in the lungs. Adv
Drug Deliv Rev. 55: 851–867.
Newman SP, Wilding IR (1998). Gamma scintigraphy: an in vivo technique for
assessing the equivalence of inhaled products. Int J Pharm. 170: 1–9.
Newman SP, Wilding IR (1999). Imaging techniques for assessing drug delivery in
man. Pharm Sci Technol Today 2: 181–189.
NIOSH (2005). Strategic Plan for NIOSH Nanotechnology Research and Guidance –
Filling the Knowledge Gap. Nanotechnology Research Program, Centers for Disease
Control and Prevention, National Institute for Occupational Safety and Health, pp.
103.
Niwa T, Shimabara H, Kondo M, Danjo K (2009). Design of porous microparticles
with single-micron size by novel spray freeze-drying technique using four-fluid
nozzle. Int J Pharm. 382 (1-2): 88-97.
Nov´akov L, Matysov L and Solich P (2006). Advantages of application of UPLC in
pharmaceutical analysis. Talanta. 68: 908–918.
Nyberg L (1984). Pharmacokinetic parameters of terbutaline in healthy man. An
overview. Eur J Respir Dis. 65 (134): 149–160.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 200
Oberdörster G (2007). Biokinetics and effects of nanoparticles. In Nanotechnology—
Toxicological Issues and Environmental Safety edited by P.P. Simeonova, N.
Opopol, M.I. Luster, Springer, Netherlands, pp. 15–51.
Okamoto H, Danjo K (2008). Application of supercritical fluid to preparation of
powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev. 60:
433–446.
Okuyama K, Wuled Lenggoro I (2003). Preparation of nanoparticles via spray route.
Chem Eng Sci. 58: 537–547.
Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA (2001).
Diffusion of macromolecules and virus-like particles in human cervical mucus.
Biophys J. 81: 1930–7.
Orlovius AK, Guddat S, Parr MK, Kohler M, Gütschow M, Thevis M, Schnzer W
(2009). Terbutaline sulfoconjugate: characterization and urinary excretion monitored
by LC/ESI-MS/MS. Drug Test Anal. 1: 554–568.
Ostrander KD, Bosch HW, Bondanza DM (1999). An in-vitro assessment of a
nanocrystal beclomethasone dipropionate colloidal dispersion via ultrasonic
nebulization. Eur J Pharm Biopharm. 48: 207–215.
Overhoff KA, Engstrom JD, Chen B, Scherzer BD, Milner TE, Johnston KP,
Williams III RO (2007). Novel ultra-rapid freezing particle engineering process for
enhancement of dissolution rates of poorly water-soluble drugs. Eur J Pharm
Biopharm. 65: 57–67.
Pacifici GM, Eligi M, Giuliani L (1993). (+) and (-) terbutaline are sulfated at a higher
rate in human intestine than in liver. Eur J Clin Pharmacol. 45: 483-487.
Palakodaty S, York P (1999). Phase behavioral effects on particle formation processes
using supercritical fluids. Pharm Res. 16: 976-985.
Palakurthi S, Govardhanachary M, Vyas SP, Diwan PV (2000). Biodistribution of
liposomes of terbutaline sulfate in guinea pigs. Drug Dev Ind Pharm. 26 (10): 1099-
1105.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 201
Panagiotou T, Fisher RJ (2008). Form nanoparticles via controlled crystallization.
Chem Eng Prog. 104: 33–39.
Parkes WR (1994). Morphology of the respiratory tract. In Occupational Lung
Disorders, (3rd Edn.), pp. 1–17.
Pasquali I, Bettini R, Giordano F (2008). Supercritical fluid technologies: an
innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug
Deliv Rev. 60: 399–410.
Pathak P, Meziani MJ, Desai T, Sun YP (2006). Formation and stabilization of
ibuprofen nanoparticles in supercritical fluid processing. J Supercrit Fluids. 37: 279-
286.
Patravale VB, Date AA, Kulkarni RM (2004). Nanosuspensions: a promising drug
delivery strategy. J Pharm Pharmacol. 56: 827–840.
Patton JS, Bukar J, Nagarajan S (1999). Inhaled insulin. Adv Drug del Rev. 35: 235-
247.
Peart J, Clarke MJ (2001). New developments in dry powder inhaler technology. Am
Pharm Rev. 4: 37–45.
Perez-Gil J (2008). Structure of pulmonary surfactant membranes and films: the role
of proteins and lipid–protein interactions. Biochim Biophys Acta. 1778: 1676–95.
Physicians Desk Reference (2002). 56th Edn., pp. 2313-2315.
Pilcer G, Amighi K (2010). Formulation strategy and use of excipients in pulmonary
drug delivery. Int J Pharm. 392: 1–19.
Pilcer G, Vanderbist F, Amighi K (2008). Correlations between cascade impactor
analysis and laser diffraction techniques for the determination of the particle size of
aerosolised powder formulations. Int J Pharm. 358: 75–81.
Pitcairn GR, Lankinen T, Seppala OP, Newman SP (2000). Pulmonary drug delivery
from the Taifun dry powder inhaler is relatively independent of the patient’s
inspiratory effort. J Aerosol Med. 13: 97–104.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 202
Plumb R, Castro-Perez J, Gragner J, Beattie I, Joncour K, Wright A (2004). Ultra-
erformance liquid chromatography coupled to quadrupole-orthogonal time-of-flight
mass spectrometry. Rapid Com Mass Spec. 19: 2331–2337.
Qamar W, Sultana S (2008). Farnesol ameliorates massive inflammation, oxidative
stress and lung injury induced by intratracheal instillation of cigarette smoke extract
in rats: An initial step in lung chemoprevention. Chem. Biol. Interact. 176: 79-87.
Quintanar-Guerrero D, Fessi H, Alemann E, Doelker E (1996). Influence of
stabilizing agent and preparative variables on the formation poly(D,L-Lactic acid)
nanoparticles by an emulsion-diffusion process. Int. J Pharm. 143: 133-141.
Rabinow BE (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov. 3:
785–796.
Radhakrishnan R (1991). Novel liposome composition for the treatment of interstitial
lung diseases. US5049389.
Radhakrishnan R, Mihalko PJ, Abra RM (1993). Corticosteroid inhalation treatment
method. US5192528.
Rasenack N., Mueller B.W (2004). Micron-size drug particles: common and novel
micronization techniques. Pharm Dev Technol. 9: 1–13.
Raula J, Eerikainen H, Kauppinen EI (2004). Influence of the solvent composition on
the aerosol synthesis of pharmaceutical polymer nanoparticles. Int J Pharm. 13: 13-
21.
Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR (2004). Etoposide
incorporated tripalmitin nanoparticles with different surface charge: formulation,
characterization, radiolabeling, and biodistribution studies. AAPS J. 6: e23.
Reverchon E, Adami R. (2006), Nanomaterials and supercritical fluids. J Supercrit
Fluids. 37 (1–22): 112–114.
Reverchon E, Donsi G (1993). Salicylic acid solubilization in supercritical CO2 and
its micronization by RESS. J Supercrit. Fluids. 6: 241-248.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 203
Reverchon E, Porta GD (2003). Terbutaline microparticles suitable for aerosol
delivery produced by supercritical assisted atomization. Int Jour Pharm. 258 (1-2):
1-9.
Reverchon E, Porta GD, Taddeo T (1995). Solubility and micronization of
griseofulvin in supercritical CHF3. Ind Eng Chem Res. 34: 4087-4091.
Rodriguez-Hornedo N, Sinclair BD (2002). Crystallization: significance in product
development, processing and performance. In Encyclopedia of pharmaceutical
technology edited by J. Swarbrick & J.C. Boylan, Dekker, New York.
Rogers TL, Nelsen AC, Hu J, Brown JN, Sarkari M, Young TJ, Johnston KP,
Williams III RO (2002). A novel particle engineering technology to enhance
dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur J Pharm
Biopharm. 54: 271–280.
Rosenborg J (2002). Clinical-pharmacokinetic aspects of prolonged effect duration as
illustrated by β2-agonists. Eur J Clin Pharmacol. 58 (4): 1-21.
Ryrfeldt A, Nilsson E (1978). Uptake and biotransformation of ibuterol and
terbutaline in isolated perfused rat and guinea pig lungs. Biochem Pharmacol. 27:
301-305.
Ryrfelt A, Ramsay CH. Distribution of terbutaline, Eur. J. Respir. Dis., 65 (Suppl
134), 63-72, 1984.
Sahin S, Selek H, Ponchel G, Ercan MT, Sargon M, Hincal AA, Kas HS (2002).
Preparation, characterization and in vivo distribution of terbutaline sulfate loaded
albumin microspheres. Jour Control Rel. 82 (2-3): 345-358.
Sakagami M (2006). In vivo, in vitro and ex vivo models to assess pulmonary
absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug
Deliv Rev. 58: 1030–1060.
Sakagami M (2006). In vivo, in vitro and ex vivo models to assess pulmonary
absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug
Deliv Rev. 58: 1030–1060.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 204
Schmid O, Moller W, Semmler-Behnke M, Ferron GA, Karg E, Lipka J, Schulz H,
Kreyling WG, Stoeger T (2009). Dosimetry and toxicology of inhaled ultrafine
particles. Biomarkers. 14 (1): 67–73.
Shahgaldian P, Gualbert J, Aýssa K, Coleman AW (2003). A study of the freeze
drying conditions of calixarene based solid lipid nanoparticles. Eur J Pharm
Biopharm. 55: 181–84.
Sharma R, Saxena D, Dwivedi AK, Misra A (2001). Inhalable microparticles
containing drug combinations to target alveolar macrophages for treatment of
pulmonary tuberculosis. Pharm Res. 18: 1405–1410.
Shekunov BY, York P (2002). Crystallization processes in pharmaceutical technology
and drug delivery design. J Crystal Growth. 211: 122-136.
Shikov AN, Pozharitskaya ON, Miroshnyk I, Mirza S, Urakova IN, Hirsjärvi S,
Makarov VG, Heinämäki J, Yliruusi J, Hiltunen R (2009). Nanodispersions of
taxifolin: Impact of solid-state properties on dissolution behavior. Int J Pharm. 377
(1-2): 148-152.
Simis K, Lei M, Lu AT, Sharma KCV, Hale RL, Timmons R, Cassella J (2008).
Nicotine aerosol generation from thermally reversible zinc halide complexes using the
staccato® system. Drug Dev Ind Pharm. 34: 936–942.
Singh DJ, Parmar JJ, Hegde DD, Lohade AA, Soni P, Samad A, Mala MD (2010).
Development and Evaluation of Dry Powder Inhalation System of Terbutaline
Sulphate for Better Management of Asthma. Int J Adv Pharm Sci. 2: 133-141.
Sinswat P, Overhoff KA, McConville JT, Johnston KP, Williams III RO (2008).
ebulization of nanoparticulate amorphous or crystalline tacrolimus—singledose
pharmacokinetics study in mice. Eur J Pharm Biopharm. 69: 1057–1066.
Smyth HD, Hickey AJ (2005). Carriers in drug powder delivery: implications for
inhalation system design. Am J Drug Deliv. 3 (2): 117–132.
Snell NJC, Ganderton D (1999). Assessing lung deposition of inhaled medications:
consensus statement from a workshop of the British association for Lung research,
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 205
held at the Institute of Biology, London, U.K. On 17 April 1998, Respir Med. 93
123–133.
Spisso BF, Lopes CC, Marques MA, Neto FR (2000). Determination of beta2-
agonists in bovine urine: comparison of two extraction/clean-up procedures for high-
resolution gas chromatography-mass spectrometry analysis. Journ Anal Toxicol. 24:
146–52.
Stahl, K, Claesson M, Lilliehorn P, Linden H, Backstrom K (2002). The effects of
process variables on the degradation and physical properties of spray dried insulin
intended for inhalation. Int J Pharm. 233: 227-237.
Stainmesse S, Orecchioni AM, Nakache E, (1992). Modelling of an original process
to obtain biocompatible polymeric nanospheres. Proc Sixth Congr Int Technol
Pharm. 1: 89–97.
Stamenkovic I (2003). Extracellular matrix remodelling: the role of matrix metallo-
proteinases. J Pathol. 200: 448–64.
Staniforth, J.N (1995). Development of dry powder inhalers. WO9511666.
Stevenson DD, Szczeklik A (2006). Clinical and pathologic perspectives on aspirin
sensitivity and asthma. J Allergy Clin Immunol. 118 (4): 773–86.
Stoica C, Verwer P, Meekes H (2004). Understanding the effect of a solvent on the
crystal habit. Crys Growth Design. 4 (4):765–768.
Su CS, Tang M, Chen YP (2009). Micronization of nabumetone using the rapid
expansion of supercritical solution (RESS) process. The J Supercrit Fluids. 50 (1):
69-76.
Subramaniam B, Rajewski RA, Snavely K (1997). Pharmaceutical processing with
supercritical carbon dioxide. J Pharm Sci. 86: 885-890.
Taburet AM, Schmit B (1994). Pharmacokinetic optimization of asthma treatment.
Clin Pharmacokinet. 26: 396-418.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 206
Takenaka S, Karg E, Kreyling WG, Lentner B, Moller W, Behnke-Semmler M
(2006). Distribution pattern of inhaled ultrafine gold particles in the rat lung. Inhal
Toxicol. 18: 733–40.
Tam JM, Engstrom JD, Ferrer D, William III RO, Johnston KP (2010). Templated
open flocs of anisotropic particles for pulmonary delivery with pressurized metered
dose inhalers. J Pharm Sci. 99: 3150–3165.
Tam JM, McConville JT, Williams III RO, Johnston KP (2008). Amorphous
cyclosporine nanodispersions for enhanced pulmonary deposition and dissolution. J
Pharm Sci. 97: 4915–4933.
Taylor J, Kotch A, Rice K, Ghafouri M, Kurland CL, Fagan NA, Witek TJ (2002).
Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in
patients with COPD. Chest. 120: 1253-1261.
Tetley TD (2002). Macrophages and the pathogenesis of COPD. Chest. 121: 156S–
9S.
Thirstrup S, Nielsen-Kudsk F, Dahl R (1997). In vitro studies on the interactions of
beta2-adrenoceptor agonists, methylxanthines, Ca2+-channel blockers, K+-channel
openers and other airway smooth muscle relaxants in isolated guinea-pig trachea. Eur
J Pharmacol. 20, 326(2-3): 191-200.
Thybo P, Hovgaard L, Lindeløv J, Brask A, Andersen S (2008). Scaling up the spray
drying process from pilot to production scale using an atomized droplet size criterion.
Pharm Res. 25: 1610–1620.
Timsina MP, Martin GP, Marriott C (1994). Drug-delivery to the respiratory-tract
using dry powder inhalers. Int J Pharm. 101 (1): 1–13.
Tozuka Y, Miyazaki Y, Takeuchi H (2010). A combinational supercritical CO2
system for nanoparticle preparation of indomethacin. Int. J Pharm. 386(1-2): 243-8.
Tristan P, Burrows JLL, French EB, Seville PC (2008). Chitosan-based spray-dried
respirable powders for sustained delivery of terbutaline sulfate. Eur Journ Pharm
Biopharm. 68 (2): 224-234.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 207
Trofast Jan (1998). New formulation for inhalation having a poured bulk density of
from 0.28 to 0.38 g/ml, comprising Formoterol. WO9831351.
Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA (2002). Trojan particles:
large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci. 99:
12001–5.
Tung HH, Paul EL, Midler M, McCauley JA (2009). Crystallization of Organic
Compounds, Wiley & Sons Inc., USA.
Ultra Performance LCTM by design (2004). Waters Corporation, USA, 720000880 EN
LL & LW-UL.
USFDA (2011). Guidance for Industry Bioanalytical Method Validation.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/G
uidances/UCM070107.pdf
Usmani OS (2009). In Delivery of drugs to the airways edited by O.S. Usmani,
Lung Biol Health Dis., pp. 143–161.
USP (2005). <601> aerosols, nasal sprays, metered-dose inhalers, and dry powder
inhalers, U.S. Pharmacopeia, pp. 32.
Van der Schans CP (2007). Bronchial mucus transport. Respir Care. 52: 1150–6.
Van der Velden V, Hulsmann AR (1999). Peptidases: structure, function and
modulation of peptide-mediated effects in the human lung. Clin Exp Allergy. 29:
445–56.
Varshosaz J, Hassanzadeh F, Mahmoudzadeh M, Sadeghi A (2009). Preparation of
cefuroxime axetil nanoparticles by rapid expansion of supercritical fluid technology.
Powder Tech. 189 (1): 97-102.
Varum FJ, McConnell EL, Sousa JJ, Veiga F, Basit AW (2008). Mucoadhesion and
the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst. 25: 207–58.
Vehring R (2008). Pharmaceutical particle engineering via spray drying, Pharm Res.
25: 999–1022.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 208
Verma S, Gokhale R, Burgess DJ (2009a). A comparative study of top-down and
bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm.
380 (1-2): 216-222.
Verma S, Lan Y, Gokhale R, Burgess DJ (2009). Quality by design approach to
understand the process of nanosuspension preparation. Int J Pharm. 377 (1-2): 185-
198.
Videira MA, Botelho MF, Santos AC, Gouveia LF, de Lima JJP, Almeida AJ (2002).
Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J
Drug Target. 10: 607–613.
Virchow JC, Kroegel C, Matthys H (1994). Antiasthma drug delivery: what is on the
horizon. Clin. Pharmacokinet. 27: 85-93.
Vogt M, Kunath K, Dressman JB (2008). Dissolution enhancement of fenofibrate by
micronization, cogrinding and spray-drying: Comparison with commercial
preparations. Eur J Pharm Biopharm. 68(2): 283-288.
Wanawongthai C, Pongpeerapat A, Higashi K, Tozuka Y, K. Moribe K, Yamamoto K
(2009). Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground
mixture. Int. J Pharm. 376(1-2): 169-175.
Wang Z, Zhang Z, Fu Z, Chen D, Zhang X (2003). Flow-injection
chemiluminescence detection for studying protein binding of terbutaline sulfate with
on-line microdialysis sampling. J Pharm Biomed Anal. 24, 33 (4): 765-73.
Wang Z, Zhang Z, Fu Z, Zhang X (2004). Sensitive flow-injection
chemiluminescence determination of terbutaline sulfate based on enhancement of the
luminol-permanganate reaction. Anal Bioanal Chem. 378 (3): 834-40.
Weers JG, Tarara TE, Clark AR (2007). Design of fine particles for pulmonary drug
delivery. Expert Opin Drug Deliv. 4: 297–313.
Wiedmann TS, DeCastro L, Wood RW (1997). Nebulization of NanoCrystals™:
production of a respirable solid-in-liquid-in-air colloidal dispersion. Pharm Res. 14:
112–116.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 209
Y.J. Son, J.T. McConville (2009). Development of a standardized dissolution test
method for inhaled pharmaceutical formulations. Int J Pharm. 382: 15–22.
Yacobi NR, Demaio L, Xie J, Hamm-Alvarez SF, Borok Z, Kim KJ (2008).
Polystyrene nanoparticle trafficking across alveolar epithelium. Nanomedicine. 4:
139–45.
Yang HJ, Chu GW, Zhang JW, Shen ZG, Chen JF (2005). Micromixing efficiency in
a rotating packed bed: experiments and simulation. Ind Eng Chem Res. 44: 7730–
7737.
Yang W, Johnston KP, Williams III RO (2010). Comparison of bioavailability of
amorphous versus crystalline itraconazole nanoparticles via pulmonary administration
in rats. Eur J Pharm Biopharm. 75: 33–41.
Yang W, Peters JI, Williams RO (2008a). Inhaled nanoparticles —a current review,
Int J Pharm. 356: 239–247.
Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, Williams III RO
(2008). High bioavailability from nebulized itraconazole nanoparticle dispersions
with biocompatible stabilizers. Int J Pharm. 361: 177–188.
York P (1999). Strategies for particle design using supercritical fluid technologies.
Pharm Sci Tech Today. 2: 430-440.
Yudin AI, Hanson FW, Katz DF (1989). Human cervical mucus and its interaction
with sperm: a fine-structural view. Biol Reprod. 40: 661–71.
Zeng XM, Martin GP, Marriott C, Pritchard J (2000). The influence of carrier
morphology on drug delivery by dry powder inhalers. Int J Pharm. 200: 93–106.
Zhang HX, Wang JX, Zhang ZB, Le Y, Shen ZG, Chen JF (2009). Micronization of
atorvastatin calcium by antisolvent precipitation process. Int. J Pharm. 374 (1-2):
106-113.
Zhang JY, Shen ZG, Zhong J, Hu TT, Chen JF, Ma ZQ, Yun J (2006). Preparation of
amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method
without surfactants. Int. J Pharm. 323 (1-2): 153-160.
Chapter 7 References
Md. Faiyazuddin (Ph.D. Thesis). Development of submicronized inhalable formulations with improved aerosolization performance (2012). 210
Zhang ZB, Shen ZG, Wang JX, Zhang HX, Zhao H, Chen JF, Yun J (2009a).
Micronization of silybin by the emulsion solvent diffusion method. Int. J Pharm. 376
(1-2): 116-122.
Zhao H., Shao L., Chen J.F., High-gravity process intensification technology and
application, Chem. Eng. J. 156 (2010) 588–593.